InThePress

July 2, 2021

New paper on HNSCC

Our paper on combined prognostic signatures (clinical, biology, radiomics variables) on Head and Neck Cancer stage III-IVA is out (n=666 retrospective + 143 prospective patients, p<0.01, […]
June 1, 2021

Our article “Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost–Utility Study”

Our article “Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost–Utility Study” […]
April 17, 2021

Brightlands, Maastricht Health Campus

Eureka Today, Expert: Jan Theys In 1996 Jan Theys started his research as a PhD student in Leuven. In short: he uses the non-pathogenic bacterium Clostridium […]
October 12, 2020

Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis

Read the article on our ERC grant “Clostridium-based Immunotherapy” which has been published on the CORDIS website in six languages at: https://lnkd.in/g5AQSvR
October 5, 2020

Bijna twee miljoen euro voor kankeronderzoek in het Maastricht UMC+

Is schildklierkanker te ruiken in uitademingslucht? Zijn bacteriën naar tumoren te sturen om daar medicijnen te produceren? KWF Kankerbestrijding investeert 1,8 miljoen euro in 3 onderzoeken […]
October 5, 2020

Obtaining research grants in times of corona

https://www.maastrichtuniversity.nl/news/obtaining-research-grants-times-corona
BUY NOW